Liver fibrosis in vivo
Since there are no specific anti-fibrotic therapy options for the liver, there is an urgent need for drugs that can delay or even reverse liver fibrosis. That is why we offer two different liver fibrosis mouse models to test drug candidates for their efficacy to inhibit the development of fibrosis in the liver or even to initiate the regression of fibrosis. You can select from two toxin-induced liver fibrosis models (LFM): carbon tetrachloride (CCL4) and thioacetamide (TAA). Both models differ in the dynamics of the severity of the liver fibrosis induced and, thus, also reflect the heterogeneity in the speed of the development of liver fibrosis in humans.
Liver fibrosis ex vivo
For ex vivo analysis of liver fibrosis, we offer Precision Cut Liver Slices (PCLS) models. PCLS are three-dimensional tissue explants derived from animal liver that can be cultured ex vivo for a certain time. They retain the anatomical architecture of the liver and its specific features, such as metabolic activity, tissue homeostasis, and, to a certain extent, immunological functions. Each liver provides enough slices to test several experimental conditions in a comparative manner. Due to its ability to closely recapitulate in vivo conditions, we use PCLS as a model for toxicological and pharmaceutical research and as an alternative to animal models in compound screening.
Effect of reference compound (Galunisertib) in PCLS on fibrosis markers (αSma and Collagen1a1) after induction of fibrosis for up to 96 hours
If you are interested in lung fibrosis models, see here for other fibrosis models, please inquire. Our fibrosis platform is complemented by numerous in vitro and ex vivo assays.
